Skip to content
Hair Pipeline
enfr
← Back to the pipeline

Daxdilimab

Daxdilimab is in Phase 2 for alopecia areata, developed by Amgen.

An antibody that removes the cell type suspected of fuelling the attack, tested open-label in 30 patients, with results posted and no programme announced since.

Phase 2BiologicInjectableImmunomodulator

This programme is no longer being actively pursued.

Monthly digest of verified phase changes. A confirmation link goes out first; unsubscribe is one click on every mail.

Developed by
Amgen
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Mechanism
Immunomodulator

Retunes the immune system more broadly than a single pathway.

Indications
Alopecia areata
Also known as
HZN-7734, VIB7734
Last public activity
January 2025
Copy last reviewed
September 2026
Record confidence
High

A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.

How it is meant to work

Daxdilimab targets ILT7 and depletes plasmacytoid dendritic cells, the main producers of type I interferon, by Amgen's description. Those cells appear in the infiltrate around affected follicles, which is the argument for removing them rather than inhibiting the signalling downstream of them.

Why it matters

This is the most upstream intervention in the register for alopecia areata. A JAK inhibitor blocks a signal continuously and has to keep being taken; depleting the cell that produces the signal is a different bet about how the disease sustains itself. The Phase 2 was a single-arm, open-label study of 30 patients, completed in January 2024; results posted to the registry in January 2025 show a mean SALT change of minus 12.6% at week 24, with a fifth of patients reaching a 50% improvement, and Amgen's 2024 pipeline lists daxdilimab in lupus and dermatomyositis, not alopecia areata. Listed as inactive on that basis.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT05368103 — Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT05368103Phase 2Completed

    Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

    Amgen · n=30 · April 2022

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources

Related programmes

Other programmes in the register with the same mechanism: Immunomodulator.

Cite this page

Hair Pipeline, "Daxdilimab — development record", hairpipeline.com/pipeline/daxdilimab